Juan Lama
Advisor @Navega Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Advisor @Navega Therapeutics
Navega Therapeutics is developing the first gene therapy for chronic pain. Navega utilizes zinc-finger and CRISPR technology for the epigenetic repression of human genes involved in the ability to feel pain.
EDUCATION
Universidad Autónoma de Madrid
Ph.D., Molecular Virology
Universidad Autónoma de Madrid
Bachelor of Science - BS, Molecular Biology -Biochemistry
Stony Brook University
Molecular Virology
SKILLS
ABOUT JUAN LAMA
Molecular virologist supporting the efforts of companies developing the antivirals and vaccines of the futurehttps://bsky.app/profile/juanlama.bsky.social Founder of RetroVirox, a contract research organization (CRO) exclusively focused on virology. The company offers a broad portfolio of antiviral assays under both, fee-for-service and full-time equivalent (FTE) pricing models. RetroVirox conducts antiviral and neutralization assays against a wide range of human viruses using live infectious virus and pseudoviruses, including influenza A and B, HIV, RSV, coronaviruses (SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-OC43), herpesviruses (CMV, HSV-1, HSV-2), flaviviruses (dengue, Zika, and West Nile virus), human rhinovirus (HRV), adenovirus (including AAV), and human metapneumovirus (HMPV). Neutralization ssays against Lassa, Ebola, SARS-CoV-1, MERS, and H5N1 influenza are offered with pseudoviruses. The company also provides customized services, including the generation of drug-resistant viruses, and the optimization of assays against novel viral agents.Since 2020, RetroVirox has evaluated thousands of experimental drugs and vaccines for biotechnology, pharmaceutical companies and academic institutions in 22 countries.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.